Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 1, 13 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 1, 13 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Severe Acute Respiratory Syndrome (SARS) - Overview
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
Severe Acute Respiratory Syndrome (SARS) - Drug Profiles
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones
Appendix
Severe Acute Respiratory Syndrome (SARS) - Overview
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
Severe Acute Respiratory Syndrome (SARS) - Drug Profiles
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Adagio Therapeutics Inc, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by AIkido Pharma Inc, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by AIM ImmunoTech Inc, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Autoimmune Technologies LLC, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Biotron Ltd, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2020 (Contd..1), H2 2020
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Adagio Therapeutics Inc, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by AIkido Pharma Inc, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by AIM ImmunoTech Inc, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Autoimmune Technologies LLC, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Biotron Ltd, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2020
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H2 2020 (Contd..1), H2 2020
LIST OF FIGURES
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
Adagio Therapeutics Inc
AIkido Pharma Inc
AIM ImmunoTech Inc
Autoimmune Technologies LLC
Biotron Ltd
CEL-SCI Corp
Citospin SL
Cocrystal Pharma Inc
Fab’entech SA
Gilead Sciences Inc
Global BioLife Inc Ltd
Immodulon Therapeutics Ltd
Lattice Biologics Ltd
Merck & Co Inc
Novartis AG
Novavax Inc
Oncovir Inc
Organicell Regenerative Medicine Inc
Pharmazz Inc
Phelix Therapeutics LLC
Pulmotect Inc
Sagimet Biosciences
Sorrento Therapeutics Inc
Theravectys SA
Trimunocor Ltd
VBI Vaccines Inc
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
Adagio Therapeutics Inc
AIkido Pharma Inc
AIM ImmunoTech Inc
Autoimmune Technologies LLC
Biotron Ltd
CEL-SCI Corp
Citospin SL
Cocrystal Pharma Inc
Fab’entech SA
Gilead Sciences Inc
Global BioLife Inc Ltd
Immodulon Therapeutics Ltd
Lattice Biologics Ltd
Merck & Co Inc
Novartis AG
Novavax Inc
Oncovir Inc
Organicell Regenerative Medicine Inc
Pharmazz Inc
Phelix Therapeutics LLC
Pulmotect Inc
Sagimet Biosciences
Sorrento Therapeutics Inc
Theravectys SA
Trimunocor Ltd
VBI Vaccines Inc
